6 December 2019
In June 2018, ARPANSA issued a direction to its licence holder, the Australian Nuclear Science and Technology Organisation (ANSTO), to initiate an independent review of its approach to occupational radiation safety at its nuclear medicine facility operated by ANSTO Health, now known as Health Products. The direction also required ANSTO to develop a plan to address the independent review team’s recommendations.
The direction came about following four separate events with safety implications at Health Products in the period August 2017 to June 2018.
On 5 December 2018, ARPANSA received ANSTO’s response to the independent review report including a draft plan – referred to as the Health Products Implementation Plan.
Over the past 12 months, ARPANSA has engaged with ANSTO to ensure the Implementation Plan provides clear measurable actions that support improved occupational radiation safety. The final version was received by ARPANSA on 30 August 2019.
Following review of the final version, the CEO of ARPANSA is now satisfied that the Implementation Plan meets the terms of the direction issued to ANSTO in June 2018. As part of this approval, Health Products’ licence conditions have been amended to include additional regulatory oversight to ensure ANSTO fulfils the commitments made in the Implementation Plan.
More information:
